James Edgemond Sells 21,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 21,000 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $470.36, for a total value of $9,877,560.00. Following the transaction, the chief financial officer owned 8,118 shares in the company, valued at approximately $3,818,382.48. This trade represents a 72.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, November 10th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $452.07, for a total transaction of $9,493,470.00.
• On Tuesday, November 4th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $436.09, for a total transaction of $9,157,890.00.

United Therapeutics Trading Up 1.0%

United Therapeutics stock traded up $4.67 on Tuesday, reaching $476.59. 599,870 shares of the stock were exchanged, compared to its average volume of 591,927. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $485.32. The firm has a fifty day moving average price of $433.93 and a two-hundred day moving average price of $351.26. The stock has a market cap of $20.52 billion, a PE ratio of 18.06, a PEG ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. During the same period last year, the business posted $6.39 earnings per share. The firm’s revenue was up 6.8% compared to the same quarter last year. Equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on UTHR. Wells Fargo & Company upped their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a research report on Thursday. Bank of America increased their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research report on Wednesday, October 29th. Finally, UBS Group boosted their price objective on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $503.90.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently made changes to their positions in the business. Integrated Investment Consultants LLC increased its stake in United Therapeutics by 32.8% in the third quarter. Integrated Investment Consultants LLC now owns 1,146 shares of the biotechnology company’s stock valued at $480,000 after acquiring an additional 283 shares during the period. Morningstar Investment Management LLC bought a new position in United Therapeutics during the third quarter worth about $1,462,000. Woodline Partners LP acquired a new stake in United Therapeutics during the third quarter valued at approximately $1,445,000. Dark Forest Capital Management LP grew its stake in shares of United Therapeutics by 348.6% in the 3rd quarter. Dark Forest Capital Management LP now owns 6,743 shares of the biotechnology company’s stock valued at $2,827,000 after purchasing an additional 5,240 shares during the period. Finally, XTX Topco Ltd raised its holdings in shares of United Therapeutics by 75.7% in the 3rd quarter. XTX Topco Ltd now owns 8,521 shares of the biotechnology company’s stock worth $3,572,000 after buying an additional 3,670 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.